EA201991181A1 - PSMA-TARGETED TRANSPECIFIC PROTEINS AND WAYS OF THEIR APPLICATION - Google Patents

PSMA-TARGETED TRANSPECIFIC PROTEINS AND WAYS OF THEIR APPLICATION

Info

Publication number
EA201991181A1
EA201991181A1 EA201991181A EA201991181A EA201991181A1 EA 201991181 A1 EA201991181 A1 EA 201991181A1 EA 201991181 A EA201991181 A EA 201991181A EA 201991181 A EA201991181 A EA 201991181A EA 201991181 A1 EA201991181 A1 EA 201991181A1
Authority
EA
Eurasian Patent Office
Prior art keywords
psma
targeted
proteins
transpecific
ways
Prior art date
Application number
EA201991181A
Other languages
Russian (ru)
Inventor
Патрик Бауэрле
Жанмари Гуно
Хольгер Веше
Роберт Б. Дабридж
Брайан Д. Лемон
Ричард Дж. Остин
Пуи Сето
Original Assignee
Харпун Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Харпун Терапьютикс, Инк. filed Critical Харпун Терапьютикс, Инк.
Priority claimed from PCT/US2017/063126 external-priority patent/WO2018098356A1/en
Publication of EA201991181A1 publication Critical patent/EA201991181A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем документе представлены нацеленные на простатический специфический мембранный антиген (PSMA) триспецифические белки, содержащие домен, связывающийся с CD3, домен, обеспечивающий увеличение времени полужизни, и домен, связывающийся с PSMA. Также представлены фармацевтические композиции на их основе, а также нуклеиновые кислоты, рекомбинантные векторы экспрессии и клетки-хозяева для получения таких PSMA-нацеленных триспецифических белков. Также раскрыты способы применения раскрытых PSMA-нацеленных триспецифических белков в предупреждении и/или лечении заболеваний, состояний и нарушений.This document presents trispecific proteins targeted to a prostate specific membrane antigen (PSMA) containing a CD3 binding domain, a half-life extension domain, and a PSMA binding domain. Also provided are pharmaceutical compositions based on them, as well as nucleic acids, recombinant expression vectors and host cells to produce such PSMA-targeted trispecific proteins. Also disclosed are methods of using the disclosed PSMA-targeted trispecific proteins in the prevention and / or treatment of diseases, conditions and disorders.

EA201991181A 2016-11-23 2017-11-22 PSMA-TARGETED TRANSPECIFIC PROTEINS AND WAYS OF THEIR APPLICATION EA201991181A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662426077P 2016-11-23 2016-11-23
PCT/US2017/063126 WO2018098356A1 (en) 2016-11-23 2017-11-22 Psma targeting trispecific proteins and methods of use

Publications (1)

Publication Number Publication Date
EA201991181A1 true EA201991181A1 (en) 2019-12-30

Family

ID=69061896

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991181A EA201991181A1 (en) 2016-11-23 2017-11-22 PSMA-TARGETED TRANSPECIFIC PROTEINS AND WAYS OF THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA201991181A1 (en)

Similar Documents

Publication Publication Date Title
MX2019006045A (en) Psma targeting trispecific proteins and methods of use.
EA201792573A1 (en) TRISPECIFIC RELATED PROTEINS AND METHODS OF THEIR APPLICATION
EA202090817A1 (en) TRISSPECIFIC PROTEINS AND METHODS OF THEIR APPLICATION
BR112018068189A2 (en) inducible binding proteins and methods of use
MX2021003554A (en) Dll3 binding proteins and methods of use.
EA201892616A1 (en) ANTIBODIES TO PD1 AND LAG3 FOR THE TREATMENT OF MALIGNANT NUMER FORMATION
EA201892561A1 (en) HYBRID PROTEINS GDF15 AND THEIR APPLICATION
EA202091710A1 (en) ANTIBODIES AGAINST CD73 AND METHODS OF THEIR USE
EA201991383A1 (en) ANTIBODIES AGAINST CTLA-4 AND WAYS OF THEIR APPLICATION
MX2020006117A (en) Targeted integration of nucleic acids.
EA201992131A1 (en) HIGH-AFFINE SPECIFIC TO MAGE-A1 TCR AND THEIR APPLICATION
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
EA201792420A1 (en) COMPOSITIONS AND METHODS OF TCR REPROGRAMMING BY MEANS OF HYBRID PROTEINS
EA201690504A1 (en) ANTIGENSYCLING PROTEINS TO GITR
EA201790799A1 (en) COMPOSITIONS AND METHODS FOR USE TO STRENGTHEN IMMUNE RESPONSE AND THERAPY OF MALIGNANT TUMORS
PH12019500571A1 (en) Anti-pd-1 antibodies
BR112019004711A2 (en) chimeric antigen receptors comprising bcma specific type III fibronectin domains and uses thereof
EA201991546A1 (en) ANTIGEN-BINDING PROTEINS AGAINST NEUROPILIN AND WAYS OF THEIR APPLICATION
EA201991409A2 (en) ANTIBODIES TO PLASMINOGEN 1 (PAI-1) ACTIVATOR INHIBITOR AND WAYS OF THEIR APPLICATION
EA201691981A1 (en) IMPROVED TRANSPORT MOLECULES OF THE MODULAR ANTIGEN AND THEIR APPLICATION
EA202190267A1 (en) METHODS AND COMPOSITIONS USING RECOMBINANT DENDRITIC CELLS FOR CANCER THERAPY
EA201591796A1 (en) ANTIBODIES TO CD52
EA202192488A1 (en) ANTIBODIES AGAINST TSG-6 AND THEIR APPLICATIONS
BR112015019719A2 (en) ENHANCED TNF-BINDING PROTEINS
EA201790241A1 (en) EFFECTIVE SELECTIVITY AGAINST RECOMBINANT PROTEINS